Template-based lymph node dissection in patients with upper tract urothelial carcinoma could facilitate better local disease control by eliminating micrometastasis, according to investigators.
After a median time of 28.4 months, 40.6% of patients treated with pembrolizumab for high-risk nonmuscle-invasive bladder cancer unresponsive to bacillus Calmette-Guérin (BCG) therapy had a complete response to the drug, and the median duration of response was 16.2 months.
A study found no survival differences between high-grade UTUC patients who at the time of radical nephroureterectomy achieved low-grade disease following neoadjuvant chemotherapy and those who had inherently low-stage disease and did not receive chemotherapy.
Investigators performed a literature review to better understand how delays in treatment might affect clinical outcomes in urologic cancer patients, including the risk of upstaging, recurrence, and mortality.
Previous retrospective studies have suggested that 5-alpha-reductase inhibitors may beneficial effects on bladder cancer development and/or recurrence, but a prospective cohort study found no protective effect.
